If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, ...
38m
Hansa Biopharma AB: PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma ...
The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...
Primary care use among patients requiring hemodialysis is associated with lower mortality, according to a recent study.
The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).
Christopher Regan, battling zero kidney function and on dialysis, seeks a living donor to transform his life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results